Disc Medicine submits NDA for bitopertin in EPP, receives priority review
PositiveFinancial Markets

Disc Medicine has submitted a New Drug Application (NDA) for bitopertin, a treatment for erythropoietic protoporphyria (EPP), and has received priority review status from the FDA. This is significant as it could lead to faster access to a much-needed therapy for patients suffering from this rare condition, highlighting the company's commitment to addressing unmet medical needs.
— Curated by the World Pulse Now AI Editorial System